Breaking News, Collaborations & Alliances

Samsung Biologics Signs Agreement with Kahr Medical

Will support Kahr’s drug candidate DSP502, a TIGITxPD1 fusion protein.

Author Image

By: Charlie Sternberg

Associate Editor

Samsung Biologics, a leading contract development and manufacturing organization, has signed a strategic partnership with Kahr Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.   Under the terms of the agreement, Samsung Biologics will provide its end-to-end cell line development and clinical drug substance and drug product manufacturing services as well as IND filling support for Kahr’s drug candidate DSP502, a TIGITxPD1 fusion protein.  ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters